celebrex with http://www.takeyourmeds.info


Take Your Meds

News for 17-Mar-21

Source: MedicineNet Kids Health General
Rest May Not Be Best for Kids After Concussion

Source: MedicineNet Kids Health General
Baby Crib Ads Show Unsafe Practices, Study Says

Source: MedicineNet Kids Health General
Some Kids' Genes Might Make Food Ads More Tempting

Source: MedicineNet Kids Health General
Child Deaths Highlight Choking Dangers Posed by Grapes

Source: MedicineNet Kids Health General
Used Safely, Donor Breast Milk Can Help Preemie Babies

Source: MedicineNet Kids Health General
Health Tip: If Your Child is Cyberbullied

Source: MedicineNet Kids Health General
Health Tip: Help Toddlers Develop Stronger Hands

Source: MedicineNet Kids Health General
Teens May Not Heed Health Warnings on Cigars

Source: MedicineNet Kids Health General
Teen Violence Can Be Contagious, Study Contends

Source: MedicineNet Kids Health General
Growth Charts

Search the Web
pharmaceutical chemistry
drug education
first aid kits
drug rehab

The Best celebrex website

All the celebrex information you need to know about is right here. Presented and researched by http://www.takeyourmeds.info. We've searched the information super highway far and wide to provide you with the best celebrex site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about

celebrex, , celebrex, , celebrex,


Take Your Meds
Most people skip taking their medication at certain times, this is bad for your health. Look to Take Your Meds on time and
Take Your Meds

Customer testimonials are a clear indication that a celebrex website is doing a good job. People who have purchased celebrex and received their goods in a prompt and efficient manner are the best advertising a business can have. In short they are saying **Buy your celebrex here**.

Long established highly reputable celebrex suppliers will even provide a contact link so that you can talk directly with the customer. This means that they are so confident that their celebrex customer has had a good experience that they are prepared to put you in direct contact with them.

Ultimately it will be your celebrex shopping experience that determines how happy you are with the supplier. We'd like to think of ourselves as intermediaries to ensure that your celebrex shopping experiences are positive ones. Our website is full of solid evidence backing up the shopping links shown above.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.


Take It Right | Kids Meet | Fantasy Football Update | Affordable Used Cars | MD Newscast

Medical Newscast   MD Meet   Present On The Net